CN108186679B - 一种祛痘组合物 - Google Patents
一种祛痘组合物 Download PDFInfo
- Publication number
- CN108186679B CN108186679B CN201810124686.3A CN201810124686A CN108186679B CN 108186679 B CN108186679 B CN 108186679B CN 201810124686 A CN201810124686 A CN 201810124686A CN 108186679 B CN108186679 B CN 108186679B
- Authority
- CN
- China
- Prior art keywords
- oil
- acne
- fullerene
- weight
- weight ratio
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 206010000496 acne Diseases 0.000 title claims abstract description 86
- 208000002874 Acne Vulgaris Diseases 0.000 title claims abstract description 85
- 239000000203 mixture Substances 0.000 title claims abstract description 59
- XMWRBQBLMFGWIX-UHFFFAOYSA-N C60 fullerene Chemical compound C12=C3C(C4=C56)=C7C8=C5C5=C9C%10=C6C6=C4C1=C1C4=C6C6=C%10C%10=C9C9=C%11C5=C8C5=C8C7=C3C3=C7C2=C1C1=C2C4=C6C4=C%10C6=C9C9=C%11C5=C5C8=C3C3=C7C1=C1C2=C4C6=C2C9=C5C3=C12 XMWRBQBLMFGWIX-UHFFFAOYSA-N 0.000 claims abstract description 56
- 229910003472 fullerene Inorganic materials 0.000 claims abstract description 44
- 239000003906 humectant Substances 0.000 claims abstract description 20
- 239000003995 emulsifying agent Substances 0.000 claims abstract description 16
- 239000002994 raw material Substances 0.000 claims abstract description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 14
- 208000002193 Pain Diseases 0.000 claims abstract description 11
- 208000003251 Pruritus Diseases 0.000 claims abstract description 10
- 231100000241 scar Toxicity 0.000 claims abstract description 9
- 230000007803 itching Effects 0.000 claims abstract description 3
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 claims description 36
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 23
- 235000015112 vegetable and seed oil Nutrition 0.000 claims description 21
- 239000008158 vegetable oil Substances 0.000 claims description 21
- -1 jojoba oil Substances 0.000 claims description 20
- 239000003921 oil Substances 0.000 claims description 19
- 235000019198 oils Nutrition 0.000 claims description 19
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 claims description 18
- 229960000458 allantoin Drugs 0.000 claims description 18
- 239000003755 preservative agent Substances 0.000 claims description 13
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 10
- NOPFSRXAKWQILS-UHFFFAOYSA-N docosan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCCO NOPFSRXAKWQILS-UHFFFAOYSA-N 0.000 claims description 10
- 235000011187 glycerol Nutrition 0.000 claims description 10
- 230000002335 preservative effect Effects 0.000 claims description 10
- 239000003795 chemical substances by application Substances 0.000 claims description 9
- 239000004205 dimethyl polysiloxane Substances 0.000 claims description 8
- XUGNVMKQXJXZCD-UHFFFAOYSA-N isopropyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC(C)C XUGNVMKQXJXZCD-UHFFFAOYSA-N 0.000 claims description 8
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical group COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 claims description 8
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 claims description 8
- 229940099259 vaseline Drugs 0.000 claims description 8
- WOWHHFRSBJGXCM-UHFFFAOYSA-M cetyltrimethylammonium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+](C)(C)C WOWHHFRSBJGXCM-UHFFFAOYSA-M 0.000 claims description 7
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 7
- 239000002202 Polyethylene glycol Substances 0.000 claims description 6
- 239000004480 active ingredient Substances 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 6
- 229940119170 jojoba wax Drugs 0.000 claims description 6
- 229920001223 polyethylene glycol Polymers 0.000 claims description 6
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 claims description 5
- 239000008168 almond oil Substances 0.000 claims description 5
- 230000003255 anti-acne Effects 0.000 claims description 5
- BTFJIXJJCSYFAL-UHFFFAOYSA-N arachidyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCO BTFJIXJJCSYFAL-UHFFFAOYSA-N 0.000 claims description 5
- 229960000735 docosanol Drugs 0.000 claims description 5
- 229930182478 glucoside Natural products 0.000 claims description 5
- 229940075529 glyceryl stearate Drugs 0.000 claims description 5
- 238000002360 preparation method Methods 0.000 claims description 5
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 claims description 5
- 230000003750 conditioning effect Effects 0.000 claims description 4
- 239000003925 fat Substances 0.000 claims description 4
- 239000000463 material Substances 0.000 claims description 4
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 claims description 4
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 claims description 4
- 229960002216 methylparaben Drugs 0.000 claims description 4
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 claims description 4
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 claims description 4
- 229940100555 2-methyl-4-isothiazolin-3-one Drugs 0.000 claims description 3
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 claims description 3
- 244000144725 Amygdalus communis Species 0.000 claims description 3
- 235000011437 Amygdalus communis Nutrition 0.000 claims description 3
- 235000019482 Palm oil Nutrition 0.000 claims description 3
- 239000010649 ginger oil Substances 0.000 claims description 3
- 239000008169 grapeseed oil Substances 0.000 claims description 3
- 239000000171 lavandula angustifolia l. flower oil Substances 0.000 claims description 3
- BEGLCMHJXHIJLR-UHFFFAOYSA-N methylisothiazolinone Chemical compound CN1SC=CC1=O BEGLCMHJXHIJLR-UHFFFAOYSA-N 0.000 claims description 3
- 239000002540 palm oil Substances 0.000 claims description 3
- 229960005323 phenoxyethanol Drugs 0.000 claims description 3
- AJBZENLMTKDAEK-UHFFFAOYSA-N 3a,5a,5b,8,8,11a-hexamethyl-1-prop-1-en-2-yl-1,2,3,4,5,6,7,7a,9,10,11,11b,12,13,13a,13b-hexadecahydrocyclopenta[a]chrysene-4,9-diol Chemical compound CC12CCC(O)C(C)(C)C1CCC(C1(C)CC3O)(C)C2CCC1C1C3(C)CCC1C(=C)C AJBZENLMTKDAEK-UHFFFAOYSA-N 0.000 claims description 2
- 235000019489 Almond oil Nutrition 0.000 claims description 2
- 241001116389 Aloe Species 0.000 claims description 2
- 244000061520 Angelica archangelica Species 0.000 claims description 2
- 235000004936 Bromus mango Nutrition 0.000 claims description 2
- 235000003880 Calendula Nutrition 0.000 claims description 2
- 240000001432 Calendula officinalis Species 0.000 claims description 2
- 235000001287 Guettarda speciosa Nutrition 0.000 claims description 2
- 235000014826 Mangifera indica Nutrition 0.000 claims description 2
- 240000007228 Mangifera indica Species 0.000 claims description 2
- 241000727169 Prinsepia utilis Species 0.000 claims description 2
- 235000019484 Rapeseed oil Nutrition 0.000 claims description 2
- 235000009184 Spondias indica Nutrition 0.000 claims description 2
- 235000019486 Sunflower oil Nutrition 0.000 claims description 2
- 235000018936 Vitellaria paradoxa Nutrition 0.000 claims description 2
- 235000019498 Walnut oil Nutrition 0.000 claims description 2
- 235000011399 aloe vera Nutrition 0.000 claims description 2
- 125000003118 aryl group Chemical group 0.000 claims description 2
- 235000021302 avocado oil Nutrition 0.000 claims description 2
- 239000008163 avocado oil Substances 0.000 claims description 2
- 235000021324 borage oil Nutrition 0.000 claims description 2
- 239000004359 castor oil Substances 0.000 claims description 2
- 235000019438 castor oil Nutrition 0.000 claims description 2
- 239000003240 coconut oil Substances 0.000 claims description 2
- 235000019864 coconut oil Nutrition 0.000 claims description 2
- 239000002285 corn oil Substances 0.000 claims description 2
- 235000005687 corn oil Nutrition 0.000 claims description 2
- 235000008524 evening primrose extract Nutrition 0.000 claims description 2
- 239000010475 evening primrose oil Substances 0.000 claims description 2
- 229940089020 evening primrose oil Drugs 0.000 claims description 2
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 claims description 2
- 239000000944 linseed oil Substances 0.000 claims description 2
- 235000021388 linseed oil Nutrition 0.000 claims description 2
- 239000004006 olive oil Substances 0.000 claims description 2
- 235000008390 olive oil Nutrition 0.000 claims description 2
- 230000008439 repair process Effects 0.000 claims description 2
- 239000003813 safflower oil Substances 0.000 claims description 2
- 239000003549 soybean oil Substances 0.000 claims description 2
- 235000012424 soybean oil Nutrition 0.000 claims description 2
- 239000002600 sunflower oil Substances 0.000 claims description 2
- 239000008170 walnut oil Substances 0.000 claims description 2
- 239000010497 wheat germ oil Substances 0.000 claims description 2
- 235000019871 vegetable fat Nutrition 0.000 claims 6
- 241001135917 Vitellaria paradoxa Species 0.000 claims 1
- 239000010474 borage seed oil Substances 0.000 claims 1
- 239000010667 rosehip oil Substances 0.000 claims 1
- 229940057910 shea butter Drugs 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 32
- 150000002148 esters Chemical class 0.000 description 49
- 210000003491 skin Anatomy 0.000 description 35
- 239000000047 product Substances 0.000 description 16
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 10
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 9
- 238000003756 stirring Methods 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 230000028327 secretion Effects 0.000 description 7
- 208000007976 Ketosis Diseases 0.000 description 6
- 210000002510 keratinocyte Anatomy 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 230000003020 moisturizing effect Effects 0.000 description 6
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 6
- 210000001732 sebaceous gland Anatomy 0.000 description 6
- 230000002195 synergetic effect Effects 0.000 description 6
- 208000020154 Acnes Diseases 0.000 description 5
- 208000032544 Cicatrix Diseases 0.000 description 5
- 102000011782 Keratins Human genes 0.000 description 5
- 108010076876 Keratins Proteins 0.000 description 5
- 239000004909 Moisturizer Substances 0.000 description 5
- 230000000844 anti-bacterial effect Effects 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 230000001333 moisturizer Effects 0.000 description 5
- 230000037387 scars Effects 0.000 description 5
- 229960003604 testosterone Drugs 0.000 description 5
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 239000003098 androgen Substances 0.000 description 4
- 230000003110 anti-inflammatory effect Effects 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 229960005309 estradiol Drugs 0.000 description 4
- 229930182833 estradiol Natural products 0.000 description 4
- 229940088597 hormone Drugs 0.000 description 4
- 239000005556 hormone Substances 0.000 description 4
- 230000002757 inflammatory effect Effects 0.000 description 4
- 230000007794 irritation Effects 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 239000011265 semifinished product Substances 0.000 description 4
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 3
- 241000186427 Cutibacterium acnes Species 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- 239000002537 cosmetic Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 230000002124 endocrine Effects 0.000 description 3
- 230000003325 follicular Effects 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 229910052740 iodine Inorganic materials 0.000 description 3
- 239000011630 iodine Substances 0.000 description 3
- 230000003780 keratinization Effects 0.000 description 3
- 235000020778 linoleic acid Nutrition 0.000 description 3
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 3
- 229910052751 metal Inorganic materials 0.000 description 3
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 3
- 229940055019 propionibacterium acne Drugs 0.000 description 3
- 229960004889 salicylic acid Drugs 0.000 description 3
- 210000002374 sebum Anatomy 0.000 description 3
- 150000003384 small molecules Chemical class 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- OHCQJHSOBUTRHG-KGGHGJDLSA-N FORSKOLIN Chemical compound O=C([C@@]12O)C[C@](C)(C=C)O[C@]1(C)[C@@H](OC(=O)C)[C@@H](O)[C@@H]1[C@]2(C)[C@@H](O)CCC1(C)C OHCQJHSOBUTRHG-KGGHGJDLSA-N 0.000 description 2
- 206010033733 Papule Diseases 0.000 description 2
- 206010037888 Rash pustular Diseases 0.000 description 2
- 229920002385 Sodium hyaluronate Polymers 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 2
- 229940030486 androgens Drugs 0.000 description 2
- 230000002421 anti-septic effect Effects 0.000 description 2
- 239000000043 antiallergic agent Substances 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 239000008139 complexing agent Substances 0.000 description 2
- 238000013329 compounding Methods 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 208000031513 cyst Diseases 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 238000007599 discharging Methods 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- UKMSUNONTOPOIO-UHFFFAOYSA-N docosanoic acid Chemical compound CCCCCCCCCCCCCCCCCCCCCC(O)=O UKMSUNONTOPOIO-UHFFFAOYSA-N 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 230000001804 emulsifying effect Effects 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 239000003205 fragrance Substances 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 210000003780 hair follicle Anatomy 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000035984 keratolysis Effects 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 230000003821 menstrual periods Effects 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- 229940127234 oral contraceptive Drugs 0.000 description 2
- 239000003539 oral contraceptive agent Substances 0.000 description 2
- 230000035699 permeability Effects 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 208000029561 pustule Diseases 0.000 description 2
- 229940010747 sodium hyaluronate Drugs 0.000 description 2
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 229960001727 tretinoin Drugs 0.000 description 2
- 230000029663 wound healing Effects 0.000 description 2
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 1
- CUNWUEBNSZSNRX-RKGWDQTMSA-N (2r,3r,4r,5s)-hexane-1,2,3,4,5,6-hexol;(z)-octadec-9-enoic acid Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O CUNWUEBNSZSNRX-RKGWDQTMSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- XEFAJZOBODPHBG-UHFFFAOYSA-N 1-phenoxyethanol Chemical compound CC(O)OC1=CC=CC=C1 XEFAJZOBODPHBG-UHFFFAOYSA-N 0.000 description 1
- NVKAWKQGWWIWPM-ABEVXSGRSA-N 17-β-hydroxy-5-α-Androstan-3-one Chemical compound C1C(=O)CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC[C@H]21 NVKAWKQGWWIWPM-ABEVXSGRSA-N 0.000 description 1
- SFAAOBGYWOUHLU-UHFFFAOYSA-N 2-ethylhexyl hexadecanoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(CC)CCCC SFAAOBGYWOUHLU-UHFFFAOYSA-N 0.000 description 1
- 108010070743 3(or 17)-beta-hydroxysteroid dehydrogenase Proteins 0.000 description 1
- ANZUDYZHSVGBRF-UHFFFAOYSA-N 3-ethylnonane-1,2,3-triol Chemical compound CCCCCCC(O)(CC)C(O)CO ANZUDYZHSVGBRF-UHFFFAOYSA-N 0.000 description 1
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
- NEZONWMXZKDMKF-JTQLQIEISA-N Alkannin Chemical compound C1=CC(O)=C2C(=O)C([C@@H](O)CC=C(C)C)=CC(=O)C2=C1O NEZONWMXZKDMKF-JTQLQIEISA-N 0.000 description 1
- 239000004229 Alkannin Substances 0.000 description 1
- 241000228245 Aspergillus niger Species 0.000 description 1
- 235000021357 Behenic acid Nutrition 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000222122 Candida albicans Species 0.000 description 1
- 108010066551 Cholestenone 5 alpha-Reductase Proteins 0.000 description 1
- 229920000832 Cutin Polymers 0.000 description 1
- 206010011732 Cyst Diseases 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 239000011703 D-panthenol Substances 0.000 description 1
- SNPLKNRPJHDVJA-ZETCQYMHSA-N D-panthenol Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCCO SNPLKNRPJHDVJA-ZETCQYMHSA-N 0.000 description 1
- 235000004866 D-panthenol Nutrition 0.000 description 1
- SUZLHDUTVMZSEV-UHFFFAOYSA-N Deoxycoleonol Natural products C12C(=O)CC(C)(C=C)OC2(C)C(OC(=O)C)C(O)C2C1(C)C(O)CCC2(C)C SUZLHDUTVMZSEV-UHFFFAOYSA-N 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 235000003956 Luffa Nutrition 0.000 description 1
- 244000050983 Luffa operculata Species 0.000 description 1
- 102000011931 Nucleoproteins Human genes 0.000 description 1
- 108010061100 Nucleoproteins Proteins 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 239000004264 Petrolatum Substances 0.000 description 1
- 235000008331 Pinus X rigitaeda Nutrition 0.000 description 1
- 235000011613 Pinus brutia Nutrition 0.000 description 1
- 241000018646 Pinus brutia Species 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 229920000289 Polyquaternium Polymers 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 108091007187 Reductases Proteins 0.000 description 1
- 235000019485 Safflower oil Nutrition 0.000 description 1
- 206010040844 Skin exfoliation Diseases 0.000 description 1
- 208000028990 Skin injury Diseases 0.000 description 1
- 244000062793 Sorghum vulgare Species 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 102000019197 Superoxide Dismutase Human genes 0.000 description 1
- 108010012715 Superoxide dismutase Proteins 0.000 description 1
- BGNXCDMCOKJUMV-UHFFFAOYSA-N Tert-Butylhydroquinone Chemical compound CC(C)(C)C1=CC(O)=CC=C1O BGNXCDMCOKJUMV-UHFFFAOYSA-N 0.000 description 1
- 230000006750 UV protection Effects 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- UNNKKUDWEASWDN-UHFFFAOYSA-N alkannin Natural products CC(=CCC(O)c1cc(O)c2C(=O)C=CC(=O)c2c1O)C UNNKKUDWEASWDN-UHFFFAOYSA-N 0.000 description 1
- 235000019232 alkannin Nutrition 0.000 description 1
- 229960003473 androstanolone Drugs 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 229940124350 antibacterial drug Drugs 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 239000010478 argan oil Substances 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 239000003899 bactericide agent Substances 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 229940116226 behenic acid Drugs 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- CDQSJQSWAWPGKG-UHFFFAOYSA-N butane-1,1-diol Chemical compound CCCC(O)O CDQSJQSWAWPGKG-UHFFFAOYSA-N 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229940095731 candida albicans Drugs 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 235000013877 carbamide Nutrition 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 229920003086 cellulose ether Polymers 0.000 description 1
- 229940059958 centella asiatica extract Drugs 0.000 description 1
- OHCQJHSOBUTRHG-UHFFFAOYSA-N colforsin Natural products OC12C(=O)CC(C)(C=C)OC1(C)C(OC(=O)C)C(O)C1C2(C)C(O)CCC1(C)C OHCQJHSOBUTRHG-UHFFFAOYSA-N 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 229960003949 dexpanthenol Drugs 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 235000004626 essential fatty acids Nutrition 0.000 description 1
- 239000010696 ester oil Substances 0.000 description 1
- 229960004756 ethanol Drugs 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 238000005189 flocculation Methods 0.000 description 1
- 230000016615 flocculation Effects 0.000 description 1
- 210000000185 follicular epithelial cell Anatomy 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000034659 glycolysis Effects 0.000 description 1
- 230000002650 habitual effect Effects 0.000 description 1
- ACCCMOQWYVYDOT-UHFFFAOYSA-N hexane-1,1-diol Chemical compound CCCCCC(O)O ACCCMOQWYVYDOT-UHFFFAOYSA-N 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- VANSZAOQCMTTPB-SETSBSEESA-N hypocrellin Chemical compound C1[C@@](C)(O)[C@@H](C(C)=O)C2=C(OC)C(O)=C3C(=O)C=C(OC)C4=C3C2=C2C3=C4C(OC)=CC(=O)C3=C(O)C(OC)=C21 VANSZAOQCMTTPB-SETSBSEESA-N 0.000 description 1
- YDLBDQPPRTYAIG-UHFFFAOYSA-N hypocrellin A Natural products COC1C2CC(C)(O)C(C(=O)C)C3=C(OC)C(=O)c4c(O)cc(OC)c5c6c(OC)cc(O)c(C1=O)c6c2c3c45 YDLBDQPPRTYAIG-UHFFFAOYSA-N 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- NUHSROFQTUXZQQ-UHFFFAOYSA-N isopentenyl diphosphate Chemical compound CC(=C)CCO[P@](O)(=O)OP(O)(O)=O NUHSROFQTUXZQQ-UHFFFAOYSA-N 0.000 description 1
- 230000001530 keratinolytic effect Effects 0.000 description 1
- 229910052747 lanthanoid Inorganic materials 0.000 description 1
- 150000002602 lanthanoids Chemical class 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 235000019713 millet Nutrition 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 229960000417 norgestimate Drugs 0.000 description 1
- KIQQMECNKUGGKA-NMYWJIRASA-N norgestimate Chemical compound O/N=C/1CC[C@@H]2[C@H]3CC[C@](CC)([C@](CC4)(OC(C)=O)C#C)[C@@H]4[C@@H]3CCC2=C\1 KIQQMECNKUGGKA-NMYWJIRASA-N 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid group Chemical group C(CCCCCCC\C=C/CCCCCCCC)(=O)O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- UWJJYHHHVWZFEP-UHFFFAOYSA-N pentane-1,1-diol Chemical compound CCCCC(O)O UWJJYHHHVWZFEP-UHFFFAOYSA-N 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 239000012466 permeate Substances 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 229940066842 petrolatum Drugs 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 229940064064 purslane extract Drugs 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 229930002330 retinoic acid Natural products 0.000 description 1
- 235000019719 rose oil Nutrition 0.000 description 1
- 239000010666 rose oil Substances 0.000 description 1
- 235000005713 safflower oil Nutrition 0.000 description 1
- 229940084038 salix alba bark extract Drugs 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 229910052706 scandium Inorganic materials 0.000 description 1
- BQJKVFXDDMQLBE-UHFFFAOYSA-N shiraiachrome A Natural products COC1=C2C3=C(OC)C=C(O)C4=C3C3=C5C(CC(C)(O)C(C(C)=O)C3=C(OC)C4=O)=C(OC)C(=O)C(C(O)=C1)=C25 BQJKVFXDDMQLBE-UHFFFAOYSA-N 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 230000037380 skin damage Effects 0.000 description 1
- 206010040882 skin lesion Diseases 0.000 description 1
- 231100000444 skin lesion Toxicity 0.000 description 1
- 229960005078 sorbitan sesquioleate Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 210000000434 stratum corneum Anatomy 0.000 description 1
- 239000004250 tert-Butylhydroquinone Substances 0.000 description 1
- 235000019281 tert-butylhydroquinone Nutrition 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- 229910052727 yttrium Inorganic materials 0.000 description 1
- OWVLYQRCCIEOPF-QHTZZOMLSA-L zinc;(2s)-5-oxopyrrolidine-2-carboxylate Chemical compound [Zn+2].[O-]C(=O)[C@@H]1CCC(=O)N1.[O-]C(=O)[C@@H]1CCC(=O)N1 OWVLYQRCCIEOPF-QHTZZOMLSA-L 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/44—Elemental carbon, e.g. charcoal, carbon black
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/31—Hydrocarbons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
- A61K8/345—Alcohols containing more than one hydroxy group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/37—Esters of carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/494—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
- A61K8/4946—Imidazoles or their condensed derivatives, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/84—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions otherwise than those involving only carbon-carbon unsaturated bonds
- A61K8/89—Polysiloxanes
- A61K8/891—Polysiloxanes saturated, e.g. dimethicone, phenyl trimethicone, C24-C28 methicone or stearyl dimethicone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/92—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof
- A61K8/922—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof of vegetable origin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/52—Stabilizers
- A61K2800/524—Preservatives
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Birds (AREA)
- Chemical & Material Sciences (AREA)
- Inorganic Chemistry (AREA)
- Emergency Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Dermatology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Cosmetics (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
本发明公开了一种祛痘组合物，该组合物包括下述重量百分比的原料制成：含富勒烯的活性成分1‑5％、乳化剂1‑5％、皮肤调理剂1‑5％、保湿剂5‑20％，余量水，该组合物具有祛痘、止痛、止痒，修复疤痕的作用。
Description
技术领域
本发明涉及祛痘领域，特别涉及含有富勒烯的祛痘组合物产品配方。
背景技术
引起痤疮及痘痘的原因有很多种，大概包括如下皮脂腺分泌旺盛；2.角质异化；3痤疮丙酸杆菌生长；4、炎症反应。根据严重程度表现分为粉刺、丘疹、结节、囊肿四个阶段皮肤损伤。在临床上根据皮肤损伤的性质和严重程度将痤疮分为三度、4级。1级(轻度)仅有粉刺；2级(中度)，除粉刺外还有一些炎症丘疹；3级(中度)除粉刺外，还有较多的炎性丘疹和/或脓包，4级(重度)，除有粉刺、炎性丘疹级脓包外，有害结节，囊肿。现有技术中主要根据形成原因而针对治疗。
1、激素分泌异常的调节体内激素分泌异常,雌二醇减少或者睾酮增多,导致皮肤中睾酮/雌二醇值升高,睾酮值相对升高,同时,毛囊和皮脂腺细胞中存在一些特异性还原酶,特别是5α-还原酶和3β、17β-羟甾类脱氢酶,这些酶可使雄激素中睾酮转化为双氢睾酮,双氢睾酮再与皮脂腺细胞内的受体结合,刺激皮脂腺细胞的增生和分泌；另外,通过促进皮肤细胞内核蛋白的合成及可供合成脂类所需能量的糖酵解通路,刺激皮脂腺细胞周期的加快及脂类合成.痤疮主要是由于雄性激素分泌异常导致的皮脂分泌异常造成,减轻病情的一种方法是增加雌性激素的调节.诺孕脂-决雌醇是首先经过FDA(food and drug administration,美国食品及药物管理局)许可的用于治疗痤疮的低剂量口服避孕药,口服避孕药明显的副作用为头痛、恶心、出血、体重增加及胸部触痛等。对痤疮的抗雄激素治疗研究表明,抗雄性激素药物主要为雄激素受体的抑制剂或拮抗剂,适用于中、轻度痤疮的治疗,具有特异性强、副作用小的优点。另外一种方法则是使用5α-还原酶和3β、17β-羟甾类脱氢酶等特异性还原酶的抑制剂,例如,根据分子结构,5α-还原酶抑制剂分为甾体和非甾体类；根据对5α-还原酶特异性不同,分为专一性5α-还原酶Ⅰ和5α-还原酶Ⅱ抑制剂及双重5α-R抑制剂。
2.针对去角质化
基底层的角质形成细胞和毛囊角质细胞异常分化,这些异常能导致皮脂中的亚油酸降低,而亚油酸是毛囊上皮细胞生长的必需脂肪酸,亚油酸缺乏可使角质形成细胞变致密,引起皮脂腺导管上皮细胞层不断增厚、管径变小、通畅度减弱,最终导致毛囊皮脂腺导管急性闭塞,毛囊隆起而形成粉刺.溶解角质可使角质层增厚改善,清除成熟粉刺,而能抑制微粉刺,提高其他合用抗痤疮药物的穿透性,例如维A酸具有角质溶解作用,不仅可以预防复发,还可以维持痤疮缓解状态,另外维A酸有中度抗炎作用,能治疗炎性皮损.使用去角质化药物应注意其新发现的副作用:过度角质化,或是服用剂量的大小会对皮肤造成一定程度的损伤,以及对其他组织的影响。
3.抗微生物及消炎
当发生痤疮时,角质形成细胞表达P物质(一种神经肽类物质),同时释放炎症因子,促进肥大细胞脱颗粒,激活中性粒细胞和巨噬细胞,也可以引发炎症反应.在没有细菌和炎症因子存在下,导管阻闭,皮脂也能单独诱导痤疮的炎症.另外,细菌的生物膜由细胞外多糖体构成,这些多糖钙架多聚体即可形成一个保护性的外骨架,起到物理性屏障作用,而影响、阻止在生物膜微环境中各种有效的抗菌药物的治疗作用.目前,有通过内服外用抗生素来实现抗菌、抗炎作用的治疗,但内服抗生素应注意其是否与复配药物有相互作用,胃肠道副作用应较小,同时使用抗生素容易产生抗药性和依赖性,一般是多种抗生素配合使用.应用蓝-红光照射等物理手段,通过光动力学可破坏痤疮丙酸杆菌及减轻炎症反应.这种光治疗法对痤疮有较好的疗效且可避免UV法潜在的放射性危害.
4.祛疤痕
痤疮治愈后,其炎症发生时破坏皮肤形成的疤痕并未消除,目前常用来修复痤疮皮损及有效预防暗斑产生的植物活性原料有:SOD(supero xide dis mutase超氧化物歧化酶)、毛青冬苷、紫草素、竹红菌甲素、毛喉萜、丝瓜皂苷、积雪草提取物等。
专利CN201410086670公开的治疗痤疮组合物包括水杨酸、戊二醇、吡咯烷酮羧酸锌、葵二醇、尿囊素中的一种或多种，该专利主要发挥了水杨酸去角质祛痘效果，加入尿囊素促进细胞生产，加快伤口愈合，软化角质蛋白的作用。但是该专利中使用水杨酸同维A酸一样具有角质溶解作用,不仅可以预防复发,还可以维持痤疮缓解状态，但是过度角质化,或是服用剂量的大小会对皮肤造成一定程度的损伤,以及对其他组织的影响，该专利中患者的痛痒感觉没有减轻，痘痕没有解决。CN201410386421公开了一种温和有效的祛痘控油组合物，包括透明质酸钠、甘油、丙二醇、羟乙基纤维线、尿素囊、D-泛醇、桃拓罗汉松提取物、乙醇、白柳树皮提取物，马齿苋提取物等。其主要通过提高皮肤的保湿效果，调节皮肤油酯平衡，抑制皮脂过渡分泌，抑制痤疮丙酸杆菌的繁殖达到控油祛痘的效果。该专利中对于中重度的痤疮治疗效果差，尤其是对疤痕的恢复效果弱。CN201510449840公开了含有富勒烯水溶性衍生物的皮肤修复剂，包括富勒烯水溶性衍生物，碘、碘稳定剂、碘络合剂、尿囊素等，该发明中含有富勒烯水溶性衍生物的皮肤修复剂中以富勒烯水溶性衍生物作为主要成分的皮肤修复剂，与强效杀菌剂碘络合剂以及含有保湿成分的尿囊素凝胶制剂配合使用，不仅能高效杀灭破损皮肤表面的创伤面的细菌，促进受损细胞的修复与再生，明显改善瘙痒等症状，该专利中没有针对痘痘或痤疮留下的痘痕修复作用。
总结以上方式，抑制雄激素类药物和抗生素等抗炎成分副作用较大，不适合长期使用，或者从针对一种机理引起的痤疮的治疗，应用受限，治愈率低。现有技术祛痘产品仅能解决祛痘的问题，之后的痘印残留是一个更加棘手的问题，同时长痘期间的痛痒感受也会降低患者的生活质量也没有得到改善。因此，目前急需一种产品能够双管齐下，能够多角度多方面解决痘痘及痘痕问题，改善患者的痛楚。
发明内容
为了解决上述技术问题，本发明的目的在于提供一种祛痘组合物，主要活性成分是由富勒烯、尿囊素配伍协同发挥疗效，该组合物可以有效的祛除痤疮，青春痘，生理期痘，内分泌失调引起的痘，并且可以快速缓解长痘期的痛痒感受，祛痘之后不留痘痕。
本发明是通过下述技术方案实现的：
一种祛痘组合物，其是由下述重量百分比的原料制成：
含富勒烯的活性成分1-5％、乳化剂1-5％、皮肤调理剂1-5％、保湿剂5-20％，余量水。
进一步优选，一种祛痘组合物，其是由下述重量百分比的原料制成：
含富勒烯的活性成分2-4％、乳化剂2-4％、皮肤调理剂2-4％、保湿剂8-15％，余量水。
进一步优选，一种祛痘组合物，其是由下述重量百分比的原料制成：
含富勒烯的活性成分3.6％、乳化剂3.25％、皮肤调理剂3.8％、保湿剂12％，余量水。
本发明所述的含富勒烯活性成分是指由富勒烯粉末、水性富勒烯或油性富勒烯中任一种与植物油酯的组合物。所述富勒烯粉末、水溶性富勒烯或油性富勒烯与植物油酯按照重量比(3-8):(0.2-1.5)组成。进一步优选，所述富勒烯粉末、水溶性富勒烯或油性富勒烯与植物油酯按照重量比(4-6):(0.5-1)组成。最佳，所述富勒烯粉末、水溶性富勒烯或油性富勒烯与植物油酯按照重量比5:1组成。
在上述技术方案中，所述的富勒烯为空心富勒烯和/或金属富勒烯。包括但不限于富勒烯C2n、M@C2n、M2@C2n、MA@C2n、M3N@C2n、M2C2@C2n、M2S@C2n、M2O@C2n和MxA3-xN@C2n中的任一种，其中，M和A均为金属元素，所述M和A均选自Sc、Y和镧系金属元素中的任意一种；30≤n≤60；0≤x≤3。
进一步优选所述富勒烯选择C60、C70、C76、C84，Gd@C82，SC3N@C80一种或以上的混合物。
所述植物油酯包括但不限于植物种子，花朵，根茎等的提取物，例如橄榄油酯，大豆油酯、亚麻籽油酯，青刺果油酯，油菜籽油酯，甜杏仁油酯，葵花油酯，红花籽油酯，葡萄籽油酯，月见草油酯，琉璃苣籽油酯，当归油酯，生姜油酯，荷荷巴油酯，核桃油酯，鳄梨油酯，芒果油酯，蓖麻油酯，杏仁油酯，乳木果油酯，玫瑰果油酯，椰子油酯，薰衣草油酯、棕榈油酯，谷糠油酯，小麦胚芽油酯，金盏花油酯，芦荟油酯，棕榈油酯，阿甘油酯，甜杏仁油酯，玉米油酯等一种或几种的混合物。进一步优选葡萄籽油酯，生姜油酯，荷荷巴油酯、薰衣草油酯中一种；最佳为荷荷巴油酯。
配方中的富勒烯具有治疗痤疮的作用，尤其是对于疤痕的恢复效果明显，但是由于富勒烯疏水性，导致吸收慢，生物活性效果低。本发明的富勒烯通过与植物油酯复配，能够将富勒烯分散到植物油酯中，能够促进富勒烯的吸收，提高生物利用度，同时植物油酯还具有协同富勒烯发挥祛痘作用。尤其是发明人发现富勒烯配伍与本发明的皮肤调理剂、保湿剂、乳化剂等辅料促进了富勒烯的吸收并产生了治疗痤疮的协同作用。
本发明所述的水性富勒烯、油性富勒烯为现有技术。可以按照WO2013/0251/80A1、CN201210406707A等制备。
本发明所述的皮肤调理剂包括但不限于尿囊素、液体石蜡、液体矿脂、豆蔻酸异丙酯、棕榈酸异丙酯、棕榈酸2-乙基己基酯、不饱和脂肪酸，如油酸棕榈酸、硬脂酸、山嵛酸、亚油酸、16/18醇、聚季铵盐-10(PQ400)等一种或几种的混合物。进一步优选皮肤调理剂包括尿囊素、16/18醇、聚季铵盐-10(PQ400)按照重量比0.1-1:1-5:0.1-0.5组成。更进一步优选皮肤调理剂是由尿囊素、16/18醇、聚季铵盐-10(PQ400)按照重量比0.5:3:0.3组成。
本发明的尿囊素还具有能直接作用于角蛋白，使其结合水的能力增强，促使角质松懈软化角质蛋白，促进细胞生长，加快伤口愈合，对于富勒烯的治疗痤疮作用起到了辅助作用。本发明所述的尿囊素是商品名，其化学名为5-尿基乙内酰胺，可购买。
所述的16/18醇起到润肤作用，具有良好触感物质，在涂抹后使皮肤呈现光滑，柔软和润滑的感觉。
上述皮肤调理剂中所述的聚季铵盐-10。聚季铵盐-10(PQ400),中文别名:氯化-2-羟基-3-(三甲氨基)丙基聚环氧乙烷纤维素醚，CAS号:68610-92-4。聚季铵盐-10溶液随着水分挥发，聚季铵盐-10因分子间相互作用而形成网状结构，形成皮膜可保持一定的水分，同时由于成膜性快速吸收的作用。聚季铵盐-10用于皮肤极佳的用后感，提高皮肤抗紫外线能力，优良的保湿滋润性能，还具有抗冲洗能力。
本发明选用的皮肤调理剂的选择及配比能够很好的协同富勒烯活性成分的治疗痤疮的作用并起到加强对疤痕的消除及改善，使皮肤润滑细腻，具优异的铺展性、润滑性、滋润型、保湿性和透气性。
本发明所述的保湿剂为甘油、丁二醇、聚乙二醇、丙二醇、已二醇、木糖醇、聚丙二醇、山梨糖醇、IPP、凡士林、聚二甲基硅氧烷、透明质酸钠中一种或以上。
进一步优选，保湿剂为甘油、凡士林、棕榈酸异丙酯、聚二甲基硅氧烷按照重量份比(2-10):(2-5):(1-5):(1-5)复配。
进一步优选，保湿剂为甘油、凡士林、棕榈酸异丙酯、聚二甲基硅氧烷按照重量份比(4-6):(2-4):(1-3):(1-3)复配。
更进一步优选，保湿剂为甘油、凡士林、棕榈酸异丙酯、聚二甲基硅氧烷按照重量份比5:3:2:2复配。
本发明的保湿剂，发明人发现在普通大量使用小分子保湿剂如甘油，丙二醇、丁二醇等，它们分子有羟基，使用在皮肤上后，依赖氢键，能够把护肤品里面的水分抓住并停留在皮肤上。此类小分子保湿剂，分子量小，渗透性强，容易进入角质细胞间隙，但是该类小分子保湿剂填加量超过8％时会产生刺激现象，尤其是在化妆品中含有油脂、乳化剂等成分时为了增强保湿性，需要加入大量的小分子成分甘油等，但随之刺激性增强。为了避免强烈的刺激性，在本发明的保湿剂组合中加入了棕榈酸异丙酯、其起到保湿和滋润皮肤的作用，皮肤对本品的吸收性较好，能在皮层内与毛囊有效接触，渗入皮层深处，并将化妆品中的活性组分带入，充分发挥有效成分的作用。凡士林、聚二甲基硅氧烷都起到顺滑肤感。本发明保湿剂的选择与皮肤调理剂中的聚季铵盐的成膜性能够更好的协调保湿作用。
本发明所述乳化剂，优选十六烷基三甲基氯化铵(1631)、山嵛醇和花生醇葡糖苷(CS200)、聚乙二醇(100)硬脂酸酯和硬脂酸甘油酯(E165)、硬质酸、失水山梨醇倍半油酸酯，聚乙二醇-30，十六烷基三甲基氯化铵,二聚羟基硬脂酸酯，卵磷脂，硬脂酸镁中一种或以上。进一步优选十六烷基三甲基氯化铵、山嵛醇和花生醇葡糖苷、聚乙二醇(100)硬脂酸酯和硬脂酸甘油酯按照重量比(0.1-1):(1-5):(0.5-2)复配。更进一步优选十六烷基三甲基氯化铵、山嵛醇和花生醇葡糖苷、聚乙二醇(100)硬脂酸酯和硬脂酸甘油酯按照重量比0.25:2:1复配。该乳化剂复配可使膏体细腻美观，使用效果最佳。其中十六烷基三甲基氯化铵具有很好的稳定性，抗絮凝剂。
作为能够配合的成分，本发明的组合物中还可以加入防腐剂、芳香剂等。
优选加入组合物的防腐剂用量0.2-1％，优选0.5-0.8％。所述防腐剂包括水溶性防腐剂、油性防腐剂。优选选择尼泊金甲酯、尼泊金丙酯、苯氧乙醇、乙基己基甘油、叔丁基对苯二酚中一种以上。为了达到较好的防腐杀菌效果，使用一种防腐剂往往严重超出安全使用剂量，带来安全隐患。进一步优选防腐剂选择尼泊金甲酯：尼泊金丙酯：苯氧基乙醇/甲基异噻唑啉酮按照重量份比为(0.5-2):(0.5-2):(2-5)复配。进一步优选，防腐剂选择尼泊金甲酯：尼泊金丙酯：苯氧基乙醇/甲基异噻唑啉酮按照重量份比1.2:1:4复配。本发明复配的防腐剂体系具有协同抗菌作用，在降低各自安全有效使用量前提下，复合使用仍然能保持足够的杀菌能力，且安全无副作用。还能避免二次污染，尤其是对霉菌的杀菌效果，延长了产品的保质期及保证了产品质量。
所述芳香剂用量为0.01-0.05％。
本发明所有的保湿剂、皮肤调理剂、乳化剂、防腐剂、芳香剂、活性物均可以市购。
有益效果
1、本发明活性成分、辅料的选择通过科学配比调制及制备工艺得到的祛痘组合物具有祛痘、止痛、止痒，修复疤痕的作用。本发明提供一种祛痘组合物祛痘疗效显著，对该组合物可以有效的祛除痤疮，青春痘，生理期痘，内分泌失调引起的痘，并且可以快速缓解长痘期的痛痒感受，祛痘之后不留印。
2、本发明组合物非常易于透过皮肤角质层，更易于吸收和利用，功效更容易发挥。
3、本发明组合物对于中重度的痤疮患者治愈效果最好、治愈率高，不复发。在极短时间内消除痤疮的红肿，缓解痛痒症状，使得痘痘快速消除，并且使用本专利产品后，祛痘之后不留任何痕迹。
4、本发明组合物刺激性小，无副作用，可长期使用。
5、本发明的组合物稳定，存储方便，高低温环境下不分层，不絮凝。
6、本发明的组合物细腻，温和、贴肤性强，易于涂抹和吸收。
7、本发明配方的复配的防腐体系，广谱抗菌，复配后用量少且安全性提高。
附图说明
图1是根据本发明组合物工艺流程图。
图2A-图2C是根据本发明的产品试用前后的效果图，图2A是使用前，图2B是使用第二天，图2C是使用1周后。
具体实施方式
下面对本发明的具体实施方式进行详细描述，但应当理解本发明的保护范围并不受具体实施方式的限制。
表1实施例1-5
制备工艺：在水相锅中投入称好的A相类原料，搅拌加热到85℃，搅拌均匀后加入C相原料，在油相锅中投入称好的B相类原料于85℃完全溶解。将乳化锅预热至60-70℃，抽真空吸入水相及油相，均质(4000r/min)搅拌，冷却至45℃加入D、E，搅拌至均匀后出料。半成品检验合格后灌装，成品检验合格后入库。
表2实施例6-10
制备工艺：在水相锅中投入称好的A相类原料，搅拌加热到85℃，搅拌均匀后加入C相原料，在油相锅中投入称好的B相类原料于85℃完全溶解。将乳化锅预热至60-70℃，抽真空吸入水相及油相，均质(4000r/min)搅拌，冷却至45℃加入D、E，搅拌至均匀后出料。半成品检验合格后灌装，成品检验合格后入库。
试验例一祛痘效果试验
药物：取实施例1的祛痘组合物，
实验组：选取20名青春期男性A组，20名青春期女性进行测试B组，该40名受试者年龄在14-24岁之间，多为激素或内分泌失调引起的痤疮。选取30名生理近生理期，女性，年龄在35-45岁C组，该30名女性习惯性经期长痘，并且以往经期过后痘消除后会形成浅斑。选取年龄在30-40岁的上班族，男性20名D组，女性20名E组，因生活工作无规律，经常熬夜加班，常出现长痘情况。以上实验者，在试用产品期间，所有饮食及生活习惯照常，均从每颗痘刚长出之时开始使用，并记录为第一天。
使用方法：局部施用，涂抹于痤疮处或痘印处，轻轻按摩至吸收即可
结果：见表3，附图2，通过对不同年龄段，及不同原因下长痘人群的实验结果可以看出，本专利产品可以在极短时间内第二天就消除痤疮的红肿，缓解痛痒症状，使得痘痘快速消除，并且使用本专利产品后，长痘后不留下任何痕迹。
表3
从表3可见，本发明的组合物对经常长痘人群效果最明显，尤其是对痘印的改善。
试验例二，本发明祛痘组合物的协同效果
采用盲测的方式，选取40名痤疮患者，分组进行实验，每组受试者10名，分别试用以下不同配比的产品见表4
对比组1：实施例1不含荷荷巴油酯
对比组2：实施例1不含有尿囊素
表4本发明组合物的协同作用
从表4可见，含有植物油酯的组合物祛痘效果强于不含有植物油酯和不含尿囊素的组合物，植物油酯与富勒烯合用具有协同作用，尿囊素能够促进本发明组合物的修复疤痕作用。从实施例1-3与实施例6的数据可见，实施例1-3的组分选择比实施例6的效果好。从实施例1-3的数据可见，实施例1的处方配比效果最好。
本发明所有实施例及权利要求范围的组合物均具有上述效果。
试验例三、防腐体系的选择试验
根据美国化妆品，盥洗品和香精联合会(CTFA法)。称取不同防腐体系的产品100g，分别加入灭菌的容器内，各加入1ml金黄色葡糖球菌，大肠杆菌，绿脓杆菌，白色念珠菌，和黑曲霉菌，摇匀。在接菌的第0、7、14、21、28天取样分析。若加菌后7天存活菌量为100CFU/g以下，在28天内全部降至0，视为优秀，通过挑战。如果在7天时存活菌量在1000以下，视为勉强通过，如果在7天时存活菌量在1000以上，视为没有通过防腐挑战。结果见表5
表5
前述对本发明的具体示例性实施方案的描述是为了说明和例证的目的。这些描述并非想将本发明限定为所公开的精确形式，并且很显然，根据上述教导，可以进行很多改变和变化。对示例性实施例进行选择和描述的目的在于解释本发明的特定原理及其实际应用，从而使得本领域的技术人员能够实现并利用本发明的各种不同的示例性实施方案以及各种不同的选择和改变。本发明的范围意在由权利要求书及其等同形式所限定。
Claims (16)
1.一种祛痘组合物，其特征在于，包括下述重量百分比的原料制成：含富勒烯的活性成分1-5％、乳化剂1-5％、皮肤调理剂1-5％、保湿剂5-20％，余量水；所述的含富勒烯的活性成分是富勒烯粉末与植物油脂的组合物，其按照重量比(3-8):(0.2-1.5)组成；所述皮肤调理剂包括尿囊素、16/18醇、聚季铵盐-10按照重量比(0.1-1):(1-5):(0.1-0.5)组成。
2.如权利要求1所述的一种祛痘组合物，其特征在于，包括下述重量百分比的原料制成：含富勒烯的活性成分2-4％、乳化剂2-4％、皮肤调理剂2-4％、保湿剂8-15％，余量水。
3.如权利要求1所述的一种祛痘组合物，其特征在于，包括下述重量百分比的原料制成：含富勒烯的活性成分3.6％、乳化剂3.25％、皮肤调理剂3.8％、保湿剂12％，余量水。
4.如权利要求1-3任意一项所述的一种祛痘组合物，其特征在于：所述富勒烯粉末与植物油脂按照重量比(4-6):(0.5-1)组成。
5.如权利要求4所述的一种祛痘组合物，其特征在于：所述富勒烯粉末与植物油脂按照重量比5:1组成。
6.如权利要求1所述的一种祛痘组合物，其特征在于：所述植物油脂为橄榄油脂，大豆油脂，亚麻籽油脂，青刺果油脂，油菜籽油脂，甜杏仁油脂，葵花油脂，红花籽油脂，葡萄籽油脂，月见草油脂，琉璃苣籽油脂，当归油脂，生姜油脂，荷荷巴油脂，核桃油脂，鳄梨油脂，芒果油脂，蓖麻油脂，杏仁油脂，乳木果油脂，玫瑰果油脂，椰子油脂，薰衣草油脂，棕榈油脂，谷糠油脂，小麦胚芽油脂，金盏花油脂，芦荟油脂，阿甘油脂，玉米油脂一种或几种的混合物。
7.如权利要求6所述的一种祛痘组合物，其特征在于：所述的植物油脂是荷荷巴油脂。
8.如权利要求1所述的一种祛痘组合物，其特征在于：所述皮肤调理剂包括尿囊素、16/18醇、聚季铵盐-10按照重量比0.5:3:0.3组成。
9.如权利要求1所述的一种祛痘组合物，其特征在于：所述的保湿剂为甘油、凡士林、棕榈酸异丙酯、聚二甲基硅烷按照重量份比(2-10)：(2-5)：(1-5):(1-5)复配。
10.如权利要求9所述的一种祛痘组合物，其特征在于：所述的保湿剂为甘油、凡士林、棕榈酸异丙酯、聚二甲基硅氧烷按照重量份比(4-6):(2-4):(1-3):(1-3)复配。
11.如权利要求10所述的一种祛痘组合物，其特征在于：所述的保湿剂为甘油、凡士林、棕榈酸异丙酯、聚二甲基硅氧烷按照重量份比5:3:2:2复配。
12.如权利要求1所述的一种祛痘组合物，其特征在于：所述乳化剂为十六烷基三甲基氯化铵、山嵛醇和花生醇葡糖苷、聚乙二醇(100)硬脂酸酯和硬脂酸甘油酯按照重量比(0.1-1):(1-5):(0.5-2)复配。
13.如权利要求12所述的一种祛痘组合物，其特征在于：所述乳化剂为十六烷基三甲基氯化铵、山嵛醇和花生醇葡糖苷、聚乙二醇(100)硬脂酸酯和硬脂酸甘油酯按照重量比0.25:2:1复配。
14.一种祛痘组合物，其特征在于：包括下述重量百分比的原料制成：含富勒烯的活性成分1-5％、乳化剂1-5％、皮肤调理剂1-5％、保湿剂5-20％，防腐剂0.2-1％，余量水，所述防腐剂为尼泊金甲酯：尼泊金丙酯：苯氧乙醇/甲基异噻唑啉酮按重量份比为(0.5-2):(0.5-2):(2-5)复配；所述的含富勒烯的活性成分是富勒烯粉末与植物油脂的组合物，其按照重量比(3-8):(0.2-1.5)组成；所述皮肤调理剂包括尿囊素、16/18醇、聚季铵盐-10按照重量比(0.1-1):(1-5):(0.1-0.5)组成。
15.一种祛痘组合物，其特征在于：包括下述重量百分比的原料制成：含富勒烯的活性成分1-5％、乳化剂1-5％、皮肤调理剂1-5％、保湿剂5-20％，防腐剂0.2-1％，芳香剂0.01-0.05％，余量水；所述的含富勒烯的活性成分是富勒烯粉末与植物油脂的组合物，其按照重量比(3-8):(0.2-1.5)组成；所述皮肤调理剂包括尿囊素、16/18醇、聚季铵盐-10按照重量比(0.1-1):(1-5):(0.1-0.5)组成。
16.如权利要求1所述的祛痘组合物在制备治疗祛痘、止痛、止痒，修复疤痕的药物上的应用。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810124686.3A CN108186679B (zh) | 2018-02-07 | 2018-02-07 | 一种祛痘组合物 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810124686.3A CN108186679B (zh) | 2018-02-07 | 2018-02-07 | 一种祛痘组合物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN108186679A CN108186679A (zh) | 2018-06-22 |
| CN108186679B true CN108186679B (zh) | 2020-08-04 |
Family
ID=62592700
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810124686.3A Active CN108186679B (zh) | 2018-02-07 | 2018-02-07 | 一种祛痘组合物 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN108186679B (zh) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109288744A (zh) * | 2018-08-23 | 2019-02-01 | 佛山市洵腾科技有限公司 | 一种控油抑痘乳液及其制备方法 |
| CN109846726A (zh) * | 2018-10-10 | 2019-06-07 | 广州雷诺生物科技有限公司 | 一种富勒烯活肤水及其制备方法 |
| CN109106613B (zh) * | 2018-10-18 | 2021-05-04 | 云南民族大学 | 一种含辣木油与山楂多糖的面膜制备方法 |
| CN109330947A (zh) * | 2018-12-03 | 2019-02-15 | 陈洁珍 | 一种控油祛痘爽肤水及其制备方法 |
| CN110876686A (zh) * | 2019-11-22 | 2020-03-13 | 广州柏俐臣化妆品科技有限公司 | 一种修复组合物及其制备方法 |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006028297A1 (ja) * | 2004-09-10 | 2006-03-16 | Vitamin C60 Bioresearch Corporation | 水溶性フラーレンとその製造方法並びに抗酸化組成物と外用組成物 |
| CN103191427A (zh) * | 2013-04-19 | 2013-07-10 | 郑州大学 | 富勒烯及其衍生物在射频或微波照射下作为制备治疗皮肤病或肿瘤药物中的应用 |
| CN105079033A (zh) * | 2015-08-13 | 2015-11-25 | 北京大学深圳研究院 | 一种复合型抗氧化组合物及其制备方法 |
| CN107308030A (zh) * | 2017-06-09 | 2017-11-03 | 佛山市汇汾化妆品科技有限公司 | 一种抗衰老活肤面霜 |
| CN107411983A (zh) * | 2017-09-12 | 2017-12-01 | 北京福纳康生物技术有限公司 | 一种水溶性富勒烯外用组合物 |
| CN107648099A (zh) * | 2017-09-30 | 2018-02-02 | 朱耀灯 | 一种控油清痘修复精华液 |
-
2018
- 2018-02-07 CN CN201810124686.3A patent/CN108186679B/zh active Active
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006028297A1 (ja) * | 2004-09-10 | 2006-03-16 | Vitamin C60 Bioresearch Corporation | 水溶性フラーレンとその製造方法並びに抗酸化組成物と外用組成物 |
| CN103191427A (zh) * | 2013-04-19 | 2013-07-10 | 郑州大学 | 富勒烯及其衍生物在射频或微波照射下作为制备治疗皮肤病或肿瘤药物中的应用 |
| CN105079033A (zh) * | 2015-08-13 | 2015-11-25 | 北京大学深圳研究院 | 一种复合型抗氧化组合物及其制备方法 |
| CN107308030A (zh) * | 2017-06-09 | 2017-11-03 | 佛山市汇汾化妆品科技有限公司 | 一种抗衰老活肤面霜 |
| CN107411983A (zh) * | 2017-09-12 | 2017-12-01 | 北京福纳康生物技术有限公司 | 一种水溶性富勒烯外用组合物 |
| CN107648099A (zh) * | 2017-09-30 | 2018-02-02 | 朱耀灯 | 一种控油清痘修复精华液 |
Also Published As
| Publication number | Publication date |
|---|---|
| CN108186679A (zh) | 2018-06-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN108186679B (zh) | 一种祛痘组合物 | |
| KR101420599B1 (ko) | 항여드름제를 함유하는 조성물 및 이의 용도 | |
| US4593046A (en) | Method of reducing skin irritation from benzoyl peroxide | |
| KR101987903B1 (ko) | 아토피 피부염 치료용 화장품 조성물 및 이의 제조 방법 | |
| MXPA04000002A (es) | Agente con un contenido de gasa (aceite), que contiene un extracto de cebolla su preparacion y su utilizacion para el cuidado, la prevencion o el tratamiento de un tejido cutaneo danado, en particular de cicatrices. | |
| EP0215108B1 (en) | Compositions for treating acne vulgaris and methods of making same | |
| CN111801108A (zh) | 局部皮肤护理组合物 | |
| BRPI1004113A2 (pt) | composiÇço de peràxido de benzoÍla para tratamento de pele | |
| BRPI1009190B1 (pt) | Solar filter composition | |
| JPH027287B2 (zh) | ||
| BRPI0617045B1 (pt) | composição, processo para preparar uma composição, uso de uma composição e uso cosmético de uma composição | |
| JP4414495B2 (ja) | 抗菌剤、並びにそれを含む皮膚外用剤及び皮膚洗浄剤 | |
| WO2008053246A1 (en) | Acne treatment | |
| WO2001019365A1 (en) | Pharmaceutical and/or cosmetical compositions | |
| US20030223953A1 (en) | Cosmetic rejuvenating and healing product, method of its manufacture and uses thereof | |
| US8383166B2 (en) | Stable hydrophobic topical herbal formulationn | |
| JP2007332078A (ja) | オゾン溶存グリセリン溶液を含む化粧料、医薬部外品、医薬（医薬品）等の外用剤 | |
| DE202006019184U1 (de) | Feuchtigkeitsspendendes Sanddorn-Hautpflegegel | |
| KR102203168B1 (ko) | 고 에탄올 함유 수중유적형 유화겔크림의 제조방법 | |
| KR101460777B1 (ko) | 여드름 개선용 화장료 조성물 | |
| CA2524375A1 (en) | Topical composition for the treatment of skin disorders and methods of using the same | |
| KR101418366B1 (ko) | 봉독 및 프로폴리스를 함유하는 여드름 예방 또는 치료용 조성물 | |
| JP2009001575A (ja) | オゾン溶存グリセリン溶液を含む化粧料、医薬部外品、医薬（医薬品）等の外用剤 | |
| WO2023104843A1 (de) | Topisch applizierbare zubereitung zur verbesserung des hautzustandes | |
| EP2399648B1 (de) | Kosmetische Zusammensetzung und deren Verwendung |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20231108 Address after: 024000 No. 9 Wanze Avenue, Hongshan Economic Development Zone, Chifeng City, Inner Mongolia Autonomous Region Patentee after: Chifeng Funakang Biotechnology Co.,Ltd. Address before: 100190 No. 2 North First Street, Haidian District, Beijing, Zhongguancun Patentee before: INSTITUTE OF CHEMISTRY, CHINESE ACADEMY OF SCIENCES Patentee before: BEIJING FULLCAN BIOTECHNOLOGY Co.,Ltd. Effective date of registration: 20231108 Address after: A-205, the second floor of the Art Museum [Suzhou High tech Zone Culture and Sports Center], No. 999, the Taihu Lake Avenue, Technopole, Suzhou Hi tech Zone, Jiangsu 215100 Patentee after: Suzhou Rensheng Zefa Biotechnology Co.,Ltd. Address before: 024000 No. 9 Wanze Avenue, Hongshan Economic Development Zone, Chifeng City, Inner Mongolia Autonomous Region Patentee before: Chifeng Funakang Biotechnology Co.,Ltd. |